DERM Stock Analysis: Buy, Sell, or Hold?
DERM - Journey Medical Corporation Common Stock
$6.70
0.27 (4.20%)
▲
5d:
+5.68%
30d:
+7.89%
90d:
-2.9%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When DERM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DERM shows positive signals but monitor for confirmation. Market pricing in 31.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: DERM shows positive signals but monitor for confirmation. Market pricing in 31.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$40.61
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$25.22
73.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DERM is currently trading at $6.70, which is considered extended relative to its 30-day fair value range of $6.00 to $6.34. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.5) compared to its historical average (20.1). Remarkably, the market is currently pricing in an annual earnings decline of 31.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DERM is in a strong downtrend. The price is approaching resistance at $6.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: DERM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.50 (+101.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DERM is in a strong downtrend. The price is approaching resistance at $6.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: DERM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.50 (+101.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.00 -
$6.34
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.2%
All Signals
- BEARISH: Price extended above range (+5.7% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.2%)
- BULLISH: Trading 101.5% below Wall St target ($13.50)
Trading Range Analysis
30-Day Trading Range
$6.00 -
$6.34
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.61
(9.1%)
Support & Resistance Levels
Support Level
$5.80
Resistance Level
$6.46
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.46
Wall Street Target
$13.50
(+101.5%)
Revenue Growth (YoY)
21.5%
Profit Margin
-14.8%
Valuation Discount vs History
-31.5% cheaper
PE vs Historical
6.5 vs 20.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-31.5%
(market-implied from PE analysis)
1-Year Target
$6.03
(-10%)
2-Year Target
$5.43
(-19%)
3-Year Target
$4.88
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→20)
$15.20
(+127%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 1496.2%)
$76.26
(+1038%)
Base:
(SPY PE: 6.5, Growth: 1496.2%)
$22.61
(+238%)
Bear:
(PE: 5.5, Growth: 1496.2%)
$19.22
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.5 to 20.1
Stabilization Target:
$20.85
(+211.3%)
PE Expansion Potential:
+211.3%
Share & Embed Analysis
Last updated: June 24, 2026 4:54 AM ET
Data refreshes hourly during market hours. Next update: 5:54 AM
Data refreshes hourly during market hours. Next update: 5:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DERM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
